1. Home
  2. TIVC vs PPCB Comparison

TIVC vs PPCB Comparison

Compare TIVC & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tivic Health Systems Inc.

TIVC

Tivic Health Systems Inc.

HOLD

Current Price

$1.40

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

PPCB

Propanc Biopharma Inc.

HOLD

Current Price

$0.11

Market Cap

1.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIVC
PPCB
Founded
2016
2007
Country
United States
Australia
Employees
N/A
2
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
1.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TIVC
PPCB
Price
$1.40
$0.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
86.9K
6.4M
Earning Date
05-14-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$780,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$0.10
52 Week High
$5.60
$10.69

Technical Indicators

Market Signals
Indicator
TIVC
PPCB
Relative Strength Index (RSI) 69.31 41.43
Support Level $0.79 N/A
Resistance Level $2.70 $0.13
Average True Range (ATR) 0.11 0.02
MACD 0.03 0.00
Stochastic Oscillator 100.00 9.76

Price Performance

Historical Comparison
TIVC
PPCB

About TIVC Tivic Health Systems Inc.

Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: